• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Halozyme Therapeutics Inc.

    11/12/24 9:36:57 AM ET
    $HALO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $HALO alert in real time by email
    SC 13G/A 1 d883368dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c)

    and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2.

    Under the Securities Exchange Act of 1934

    (Amendment No. 5 )*

     

     

    Halozyme Therapeutics Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    40637H109

    (CUSIP Number)

    9/30/2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 40637H109    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Limited Partnership

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     Not Applicable

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     None

       6  

     SHARED VOTING POWER

     

     2,613,159

       7  

     SOLE DISPOSITIVE POWER

     

     None

       8  

     SHARED DISPOSITIVE POWER

     

     3,133,412

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,133,412

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     Not Applicable

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     2.5%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     IA


    CUSIP No. 40637H109    13G   

     

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Investments GP LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     Not Applicable

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     None

       6  

     SHARED VOTING POWER

     

     2,613,159

       7  

     SOLE DISPOSITIVE POWER

     

     None

       8  

     SHARED DISPOSITIVE POWER

     

     3,133,412

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,133,412

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     Not Applicable

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     2.5%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC


    CUSIP No. 40637H109    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Holdings LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     Not Applicable

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     None

       6  

     SHARED VOTING POWER

     

     2,613,159

       7  

     SOLE DISPOSITIVE POWER

     

     None

       8  

     SHARED DISPOSITIVE POWER

     

     3,133,412

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,133,412

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     Not Applicable

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     2.5%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC


    CUSIP No. 40637H109    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Asset Management Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     Not Applicable

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     None

       6  

     SHARED VOTING POWER

     

     2,613,159

       7  

     SOLE DISPOSITIVE POWER

     

     None

       8  

     SHARED DISPOSITIVE POWER

     

     3,133,412

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     3,133,412

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions)

     Not Applicable

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     2.5%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC


    Item 1(a)

    Name of Issuer:

    Halozyme Therapeutics Inc.

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    12390 El Camino Real, San Diego, CA, 92130

     

    Item 2(a)

    Name of Person Filing:

    Artisan Partners Limited Partnership (“APLP”)

    Artisan Investments GP LLC (“Artisan Investments”)

    Artisan Partners Holdings LP (“Artisan Holdings”)

    Artisan Partners Asset Management Inc. (“APAM”)

     

    Item 2(b)

    Address of Principal Business Office:

    APLP, Artisan Investments, Artisan Holdings, and APAM are all located at:

    875 East Wisconsin Avenue, Suite 800

    Milwaukee, WI 53202

     

    Item 2(c)

    Citizenship:

    APLP is a Delaware limited partnership

    Artisan Investments is a Delaware limited liability company

    Artisan Holdings is a Delaware limited partnership

    APAM is a Delaware corporation

     

    Item 2(d)

    Title of Class of Securities:

    Common Stock

     

    Item 2(e)

    CUSIP Number:

    40637H109

     

    Item 3

    Type of Person:

    (e) APLP is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

    (g) Artisan Holdings is the sole limited partner of APLP and the sole member of Artisan Investments; Artisan Investments is the general partner of APLP; APAM is the general partner of Artisan Holdings.


    Item 4

    Ownership (at 9/30/2024):

     

      (a)

    Amount owned “beneficially” within the meaning of rule 13d-3:

    3,133,412

     

      (b)

    Percent of class:

    2.5% (based on 126,678,280 shares outstanding as of 7/31/2024)

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or to direct the vote: None

     

      (ii)

    shared power to vote or to direct the vote: 2,613,159

     

      (iii)

    sole power to dispose or to direct the disposition of: None

     

      (iv)

    shared power to dispose or to direct the disposition of: 3,133,412

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    Not Applicable

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable

     

    Item 8

    Identification and Classification of Members of the Group:

    Not Applicable

     

    Item 9

    Notice of Dissolution of Group:

    Not Applicable

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: 11/12/2024

     

    ARTISAN PARTNERS ASSET MANAGEMENT INC,
    for itself and as the general partner of
    ARTISAN PARTNERS HOLDINGS LP
    By:  

    Gregory K. Ramirez *

    ARTISAN INVESTMENTS GP LLC,
    for itself and as the general partner of
    ARTISAN PARTNERS LIMITED PARTNERSHIP
    By:  

    Gregory K. Ramirez *

    *By:  

    /s/ Gregory K. Ramirez

      Gregory K. Ramirez
      Executive Vice President of Artisan Partners Asset Management Inc.
      Vice President of Artisan Investments GP LLC


    Exhibit Index

     

    Exhibit 1    Joint Filing Agreement dated 11/12/2024 by and among Artisan Partners Limited Partnership, Artisan Investments GP LLC, Artisan Partners Holdings LP, and Artisan Partners Asset Management Inc.
    Get the next $HALO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HALO

    DatePrice TargetRatingAnalyst
    5/14/2025$62.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$47.00Market Perform → Underperform
    Leerink Partners
    10/7/2024$58.00 → $62.00Overweight → Equal Weight
    Wells Fargo
    9/19/2024$52.00 → $57.00Overweight → Neutral
    JP Morgan
    6/7/2024$48.00 → $51.00Overweight → Neutral
    Piper Sandler
    2/29/2024$54.00Outperform
    TD Cowen
    7/24/2023$61.00Buy
    H.C. Wainwright
    7/24/2023$43.00 → $45.00Buy → Neutral
    Goldman
    More analyst ratings

    $HALO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

      SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. VYVGART is

      6/20/25 1:15:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme to Participate at Upcoming Investor Conferences

      SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences. Details on the Company's participation are as follows: Event: Benchmark 2025 Healthcare House Call Virtual Conference Format: 1x1 Meetings Date: Thursday, May 29, 2025 Event: Goldman Sachs 46th Annual Global Healthcare Conference 2025 Format: Fireside Chat and 1x1 Meetings Date: Monday, June 9, 2025 Presentation Time: 7:00am PT / 10:00am ET   A live audio webcast of the presentation will be available in the Investor Relations sec

      5/28/25 4:05:00 PM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

      Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Bristol Myers Squibb received European Commission (EC) approval of a new Opdivo® (nivolumab) subcutaneous formulation developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for use across multiple adult solid tumors as monotherapy, monotherapy maintenance following completion of intravenous nivolumab plus Yervoy® (ipilimumab) combination therapy, or in combination with chemotherapy or cabozantinib. "The European approval of Opdivo SC rep

      5/28/25 8:30:00 AM ET
      $HALO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care